Article
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2023
John Thomas, Grohé Christian, Goldman Jonathan W, Shepherd Frances A, de Marinis Filippo, Kato Terufumi, Wang Qun, Su Wu-Chou, Choi Jin Hyuk, Sriuranpong Virote, Melotti Barbara, Fidler Mary J, Chen Jun, Albayaty Muna, Stachowiak Marta, Taggart Sarah, Wu Yi-Long, Tsuboi Masahiro, Herbst Roy S, Majem Margarita
Abstract excerpt
INTRODUCTION: In ADAURA, adjuvant osimertinib significantly improved disease-free survival versus placebo in resected stage IB to IIIA EGFR-mutated NSCLC. We report in-depth analyses of three-year safety, tolerability, and health-related quality of life (HRQoL) from ADAURA. METHODS: Patients were randomized 1:1 to osimertinib 80 mg or placebo once daily for up to 3 years. Safety assessments were performed at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.